Manager TitleAgeSince
Chief Executive Officer 64 31/03/2022
Director of Finance/CFO - 01/08/2024
Director TitleAgeSince
Chairman 70 20/11/2019
Director/Board Member 65 01/06/2013
Director/Board Member 80 30/12/2021
Date Insider Type Main position Quantity % Market Cap. Importance
22/6/22 Free 111,193 0.2314%
19/1/21 Sell 1 0.0000%
19/1/21 Sell 2,000 0.0179%
Change 5-day change 1-year change 3-year change Capi.($)
-75.00%-.--% - - 817K
+4.28%+0.07%+52.75%+138.78% 1,258B
+2.13%+4.27%+51.21%+91.36% 679B
+0.68%+1.54%+33.83%+112.47% 518B
-0.19%+2.71%+43.99%+69.63% 390B
+1.38%+0.27%+72.42%+45.30% 367B
+0.20%+1.64%+30.78%+59.38% 307B
-0.66%+2.08%+7.01%+39.21% 293B
+1.04%-0.05%+45.29%+76.18% 252B
+1.46%-0.59%+42.48%+125.82% 210B
Average -6.37%+1.05%+42.20%+84.24% 475B
Weighted average by Cap. +1.98%+1.18%+45.44%+96.87%
Logo Spexis AG
Spexis AG, former Polyphor AG, is a Switzerland-based clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of first-in-class molecules in oncology and antimicrobial resistance leveraging its macrocyclic peptide technology platform. The Company's medicines pipeline includes Balixafortide (POL6326), which is in a Phase III trial in combination with eribulin in patients with advanced breast cancer; Outer Membrane Protein Targeting Antibiotics (OMPTA), which is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis caused by Gram-negative bacteria; POL6014, which is an inhaled inhibitor of neutrophil elastase for the treatment of Cystic Fibrosis and other severe lung diseases, as well as Murepavadin (POL7080), which is an antibiotic with a mode of action to treat pseudomonas infections.
Employees
50
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SPEX Stock